Balyasny Asset Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Balyasny Asset Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-112,300	Closed	-$11.2M	–	2488
2021 Q1	$11.2M	Buy	+112,300	New	+$13.1M	0.06%	452
2020 Q4	–	Sell	-70,000	Closed	-$6.82M	–	1804
2020 Q3	$6.82M	Buy	+70,000	New	+$8.75M	0.05%	508
2020 Q2	–	Sell	-10,000	Closed	-$1.44M	–	1580
2020 Q1	$1.44M	Buy	+10,000	New	+$1.93M	0.02%	681

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Balyasny Asset Management's RETA Position: Q1 2023 in Review

Balyasny Asset Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2023, closing a stake of 11 shares — an estimated $418 sold.

Balyasny Asset Management first reported a position in RETA in Q1 2020 and held it in 8 quarters. The position peaked at $10.8M in Q1 2021. 205 funds tracked by Wall St. Rank hold RETA as of Q1 2023.

Balyasny Asset Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2023 after selling out during the quarter.
Balyasny Asset Management sold 11 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2023, an estimated $418.
Balyasny Asset Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2020 and held it in 8 quarters.
Balyasny Asset Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $10.8M in Q1 2021.
205 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2023.

Based on Balyasny Asset Management's 13F filing for Q1 2023, filed 15 May 2023.